Blue Trust Inc. Sells 268 Shares of Penumbra, Inc. (NYSE:PEN)

Blue Trust Inc. lessened its position in Penumbra, Inc. (NYSE:PEN) by 52.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 241 shares of the company’s stock after selling 268 shares during the quarter. Blue Trust Inc.’s holdings in Penumbra were worth $57,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. New York State Teachers Retirement System lifted its position in Penumbra by 0.4% during the fourth quarter. New York State Teachers Retirement System now owns 37,654 shares of the company’s stock valued at $8,942,000 after buying an additional 148 shares during the period. Allspring Global Investments Holdings LLC grew its position in shares of Penumbra by 39.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 299,397 shares of the company’s stock worth $71,831,000 after buying an additional 85,284 shares during the period. Savant Capital LLC increased its stake in shares of Penumbra by 8.0% in the 4th quarter. Savant Capital LLC now owns 2,981 shares of the company’s stock worth $708,000 after acquiring an additional 221 shares in the last quarter. 17 Capital Partners LLC purchased a new position in Penumbra during the 4th quarter valued at about $229,000. Finally, WCM Investment Management LLC bought a new stake in Penumbra during the fourth quarter worth about $13,451,000. 88.88% of the stock is currently owned by institutional investors.

Insider Activity at Penumbra

In other news, EVP Johanna Roberts sold 600 shares of Penumbra stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $244.49, for a total transaction of $146,694.00. Following the transaction, the executive vice president now owns 63,444 shares in the company, valued at $15,511,423.56. This trade represents a 0.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Adam Elsesser sold 15,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $242.96, for a total transaction of $3,644,400.00. Following the sale, the chief executive officer now directly owns 837,582 shares of the company’s stock, valued at approximately $203,498,922.72. The trade was a 1.76 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,219 shares of company stock worth $4,426,439. 5.00% of the stock is owned by insiders.

Penumbra Stock Performance

Shares of PEN stock opened at $281.15 on Wednesday. The firm has a market capitalization of $10.83 billion, a PE ratio of 826.92, a P/E/G ratio of 2.83 and a beta of 0.53. The company has a 50 day moving average price of $260.58 and a 200-day moving average price of $230.30. Penumbra, Inc. has a 52 week low of $148.00 and a 52 week high of $310.00. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN) last posted its earnings results on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.09. The business had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. As a group, equities research analysts expect that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Analyst Upgrades and Downgrades

PEN has been the subject of a number of analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Penumbra in a research note on Wednesday, February 19th. Robert W. Baird raised their price objective on Penumbra from $305.00 to $328.00 and gave the company an “outperform” rating in a research report on Wednesday, February 19th. UBS Group boosted their target price on Penumbra from $305.00 to $320.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Wells Fargo & Company increased their target price on Penumbra from $275.00 to $305.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. Finally, Royal Bank of Canada lifted their price target on Penumbra from $285.00 to $313.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $292.64.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.